Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
European Organization for Research and Treatment of Cancer Gruppo Italiano Malattie EMatologiche dell'Adulto |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00052299 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known if combining combination chemotherapy with monoclonal antibody therapy will kill more cancer cells.
PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy with or without gemtuzumab ozogamicin in treating patients who have acute myeloid leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: cytarabine Drug: etoposide Drug: gemtuzumab ozogamicin Drug: idarubicin Drug: mitoxantrone hydrochloride |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control |
Official Title: | Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP |
Estimated Enrollment: | 450 |
Study Start Date: | September 2002 |
OBJECTIVES:
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to age (61-69 vs 70-75), CD33 positivity (less than 5% vs 5-19% vs 20-80% vs more than 80% vs unknown), initial WBC before hydroxyurea administration if needed (less than 30,000/mm^3 vs at least 30,000/mm^3), and participating center.
Patients are randomized to 1 of 2 treatment arms.
Arm I:
Arm II:
Bone marrow evaluation is performed on day 29. Patients with PR receive a second course of MICE chemotherapy regimen. Patients with CR after 1 or 2 courses of MICE regimen proceed to consolidation therapy. Patients with progressive disease go off therapy.
Patients are followed monthly for 1 year, every 3 months for 2 years, and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 450 patients (225 per treatment arm) will be accrued for this study within 3.75 years.
Ages Eligible for Study: | 61 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of acute myeloid leukemia (AML)
FAB subtypes M0-M2 and M4-M7
Previously untreated primary or secondary AML, including AML after myelodysplastic syndromes
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Investigator: | Sergio Amadori, MD | Ospedale Sant' Eugenio |
Study Chair: | Sergio Amadori, MD | Ospedale Sant' Eugenio |
Study ID Numbers: | CDR0000258151, EORTC-06012, AML-17, GIMEMA-AML-17 |
Study First Received: | January 24, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00052299 History of Changes |
Health Authority: | United States: Federal Government |
adult acute monocytic leukemia (M5b) adult acute erythroid leukemia (M6) adult acute megakaryoblastic leukemia (M7) adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia with maturation (M2) adult acute myeloblastic leukemia without maturation (M1) adult acute myelomonocytic leukemia (M4) |
adult acute monoblastic leukemia (M5a) untreated adult acute myeloid leukemia secondary acute myeloid leukemia adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) |
Leukemia, Monocytic, Acute Antimetabolites Anti-Infective Agents Immunologic Factors Acute Myelomonocytic Leukemia Acute Monoblastic Leukemia Leukemia, Myeloid, Acute Etoposide phosphate Antibodies, Monoclonal Anti-Bacterial Agents Leukemia Acute Erythroblastic Leukemia Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Neoplasm Metastasis |
Analgesics Congenital Abnormalities Etoposide Cytarabine Immunoglobulins Leukemia, Myeloid Gemtuzumab Immunosuppressive Agents Antiviral Agents Leukemia, Myelomonocytic, Acute Idarubicin Antibodies Leukemia, Erythroblastic, Acute Peripheral Nervous System Agents Mitoxantrone |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Leukemia, Myeloid, Acute Antibiotics, Antineoplastic Antibodies, Monoclonal Leukemia Sensory System Agents Therapeutic Uses |
Analgesics Cytarabine Neoplasms by Histologic Type Leukemia, Myeloid Gemtuzumab Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Idarubicin Neoplasms Mitoxantrone Peripheral Nervous System Agents Central Nervous System Agents |